In preclinical research, a high percentage of molecules that pass the invitro phase do not pass validation in animal models. The BFlow technology used between the two tests, by applying flow dynamics modelling and physiological conditions in the device with cell culture, allows better discrimination of molecules with probable in vivo activity, with the consequent savings in time to market and experimental costs. It is a cutting-edge and effective solution, the result of years of research by its scientific team and awarded by the Royal Galician Academy of Sciences.